Mast cells are known for their detrimental effects in various inflammatory conditions. Regimens that induce selective mast cell apoptosis may therefore be of therapeutic significance. Earlier studies have demonstrated that murine-and human-cultured mast cells are highly sensitive to apoptosis induced by the lysosomotropic agent LeuLeuOMe (LLME). However, the efficacy of lysosomotropic agents for inducing apoptosis of in vivo-derived airway mast cells and the impact on mast cells in other species have not been assessed. Here we addressed whether lysosomotropic agents can induce cell death of equine in vivoderived mast cells. Bronchoalveolar lavage (BAL) fluids from horses were incubated with LLME at 15-100 lM for up to 48 h. The overall cell viability was unaffected by 15 lM LLME up to 48 h, whereas a relatively modest drop in total cell counts (~30%) was seen at the highest LLME dose used. In contrast to the relatively low effect on total cell counts, LLME efficiently and dose dependently reduced the number of mast cells in BAL fluids, with an almost complete depletion (96%) of mast cells after 24 h of incubation with 100 lM LLME. A significant but less dramatic reduction (up to~45%) of lymphocytes was also seen, whereas macrophages and neutrophils were essentially resistant. The appearance of apoptotic bodies suggested a mechanism involving apoptosis rather than necrosis. These findings suggest that equine airway mast cells are highly sensitive to lysosomotropic agents. Possibly, lysosomotropic agents could be of therapeutic value to treat disorders involving harmful accumulation of mast cells in the airways.
Introduction
Mast cells are immune cells originating from haematopoietic stem cells of the bone marrow. They are found in essentially all vascularized tissues throughout the body, mainly at sites with close contact to the external environment. They exert their functions in response to external stimuli by releasing a broad variety of granule-stored as well as de novo synthesized bioactive mediators. The mast cell granules (also referred to as secretory lysozymes) are acidic compartments storing pro-and anti-inflammatory compounds such as histamine, proteases, cytokines and growth factors [1, 2] . Mast cells are mainly associated with their role in allergy and asthma pathophysiology but there is increasing evidence connecting mast cells to other disorders, for example cancer, arthritis and atherosclerosis [3, 4] .
Therapies for reducing harmful effects of mast cells include blocking of receptors for bioactive mediators (e.g. H1 receptor antagonists and prostaglandin D2 receptor antagonists) and agents that prevent mast cell degranulation (i.e. stabilizers) [5] . However, no pharmaceuticals have so far been shown to completely block degranulation and mediator release. As an alternative to merely blocking mast cell degranulation or blocking effects of individual mast cell mediators, a possible way to eliminate detrimental mast cell responses could involve selective induction of apoptosis.
Lysosomotropic agents are compounds that, after uptake, cause lysosomal membrane destabilization, which in turn leads to the release of pro-apoptotic proteases into the cytosolic compartment followed by apoptosis [6, 7] . Previous studies have shown that certain cell types are particularly sensitive to cell death induced by this type of compounds. For example, macrophages and lymphocytes, in particular the CD8 + subtype of lymphocytes, are known to undergo cell death in response to lysosomotropic agents [6, 8] . Moreover, studies from our laboratory have demonstrated that cultured mast cells are highly sensitive to cell death induced by this type of compounds [9] [10] [11] .
The high sensitivity of mast cells to such agents is most likely explained by their high content of lysosome-like organelles (granules). However, earlier studies on the effects of lysosomotropic agents on mast cells have been focused on mouse and human cells only and have not assessed the effect on fully mature, in vivo-derived mast cells [9, 11, 12] .
The aim of this study was to investigate the effect of the lysosomotropic agent LLME on the leucocyte populations present in the bronchoalveolar lavage (BAL) fluids of horses. We show that equine mast cells are highly susceptible to lysosomotropic agents, introducing the possibility of using lysosomotropic agents to reduce detrimental effects of mast cells in the context of airway disorders of the horse.
Materials and methods
Horses and bronchoalveolar lavage. Three horses of different ages and breeds were included in this study (see Table 1 ). BAL fluid samples were collected by bronchoscopy after intravenous premedication with sedative (Detomidine and butorphanol tartrate). The BAL was performed with a blind tube (Bivona â ), with 3 9 100 ml sterile isotonic saline solution (at 37°C). Recovered BAL fluid was placed on ice, samples were pooled and an aliquot was taken for cytology. A local anaesthetic (Carbocain â , AstraZeneca, S€ odert€ alje, Sweden) was instilled at the trachea before performing BAL.
Cell morphology. Cells were collected on object slides by cytospin centrifugation (500 rpm for 5 min) and stained with May-Gr€ unwald/Giemsa as previously described [13] . Differential counting was performed using a light microscope by counting at least 200 cells/slide.
Effects of lysosomal membrane destabilization. Counting of total cells in BAL fluid was performed using a B€ urker chamber. Cells were centrifuged at 300 9 g for 7 min and the resulting cell pellet was resuspended in DMEM plus glutaMAX media (Gibco, Invitrogen, Paisley, UK) supplemented with 10% heat inactivated foetal bovine serum (FBS) at a concentration of 1 9 10 6 cells/ml. Triplicates of 1 ml BAL cells were transferred into 24-well plates and incubated with various concentrations (15, 50 and 100 lM) of H-Leu-Leu-OMe (LLME, Bachem, Bubendorf, Switzerland) for 4, 24 or 48 h. Untreated cells were used as control. Cell viability was measured after incubation of 100 ll cell suspension with 20 ll CellTiter-Blue Reagent (Promega Invitrogen, Carlsbad, CA) in a 96-well plate for 4 h at 37°C. Fluorescence was read at 560 nm excitation and at 650 nm emission.
Statistical analysis. Statistical significance was calculated with Student's t-test using GraphPad Prism 4.0 (GraphPad Software, Inc, San Diego, CA, USA). All P-values <0.05 were considered to be significant. Each experiment was performed in triplicates. All data shown are mean values from three independent experiments with BAL cells from three different horses.
Results

Differential cell count
To obtain primary cells from airways, bronchoalveolar lavage (BAL) fluid was collected from three horses diagnosed with mild airway disease ( Table 1 and Fig. 1A ). Differential counting of BAL fluid cells was performed. This showed that macrophages were the dominating cell population of the equine airways, constituting 76.7 AE 0.3% of the cells. Lymphocytes accounted for 17.4 AE 1.5% of the cells, whereas 3.6 AE 1.3% of the BAL fluid cells were mast cells. Neutrophils and eosinophils represented 1.6 AE 1.2% and 0.6 AE 0.6% of the total cells, respectively (Fig. 1) .
Effect of LLME on total cell viability LLME is a compound that induces permeabilization of lysosomes and subsequent activation of pro-apoptotic proteins [14] [15] [16] [17] . To investigate whether primary airway cells are sensible to lysosomal membrane permeabilization, we assessed the total cell viability of horse BAL fluid cells in response to different doses of LLME. As shown in Fig. 2 , no effect on total cell viability was seen for LLME up to 50 lM after 4 h of incubation. Similarly, LLME up to 50 lM did not significantly reduce the total cell viability after 24 h of incubation. After 48 h of incubation, no effect Table 1 Horse descriptions, anamnesis and differential cell count of bronchoalveolar lavage of the three horses described in the study.
Horses (n = 3) Anamnesis
Cell types in BAL (% of total cell count) Ó 2016 The Foundation for the Scandinavian Journal of Immunology of 15 lM LLME was seen, whereas 50 lM LLME produced a modest but significant drop in total cell viability. At the highest dose used (100 lM), LLME caused only a slight drop in cell viability after 4 h, whereas somewhat more pronounced effects were seen at 24 h and 48 h (Fig. 2) .
Mast cells and lymphocytes are sensitive to LLME
The data above suggest that LLME has limited overall cytotoxic activity on equine BAL fluid cells. To clarify whether LLME has general cytotoxic effects on all BAL fluid cell populations or if LLME showed selectivity for certain cell types, we performed differential cell counting on BAL fluid samples that had been incubated with LLME. As shown in Fig. 3A , macrophages were resistant to apoptosis in response to treatment with LLME for up to 48 h with LLME concentrations up to 100 lM. Notably, although, 48 h culture with 100 lM LLME slightly affected the morphology of some of the macrophages (data not shown). The increased percentage of macrophages seen after 24 h and 48 h in culture merely reflected the reduction of other cell types investigated (Fig. 3A) . In striking contrast to macrophages, mast cells were highly sensitive to LLME treatment (Fig. 3B) . After 24 h culture with 50 lM LLME, a dramatic mast cell reduction (54%) was seen, and at a LLME concentration 100 lM a nearly total depletion of mast cells was observed (Fig. 3B) . Similar effects on mast cell viability were observed after 48 h culture with LLME (Fig. 3B ). Lymphocytes were also susceptible to LLME treatment, although not to the same extent as seen for mast cells. As depicted in Fig. 3C , addition of 50 lM or 100 lM LLME caused an up to~45% reduction of BAL fluid lymphocytes, and it is notable that similar extents of cytotoxicity were seen at both 24 and 48 h. Similar to macrophages, neutrophils were resistant to the LLME treatment (Fig. 3D) . Reliable results could not be obtained for the effect of LLME on eosinophils (data not shown) due to the low number of this cell type in the BAL fluid (see Fig. 1B ). After lysosomal membrane permeabilization, we observed clear morphological evidence of apoptosis in the cell cultures, that is generation of apoptotic bodies (Fig. 3E ).
Discussion
Respiratory disorders represent major problems in the animal welfare and equine industry and are one of the main disorders causing poor performance in sporting horses [18] . Moderate inflammation in the athletic horse described as inflammatory airway disease (IAD) is a common syndrome with lower respiratory tract inflammation in sport horses [19] [20] [21] . An increased number of mast cells (>2%) has been described in horses with IAD [22] , suggesting that mast cells may contribute to the pathology of IAD. Strategies that limit the actions of mast cells in the equine airways, for example to induce selective mast cell apoptosis, may therefore represent a potential therapeutic regimen to cope with IAD. Here we addressed this issue by assessing whether lysosomotropic agents can selectively reduce mast cell populations of the equine airway. Several previous studies have shown that a number of different human and mouse immune cells are sensitive to lysosomal membrane destabilization mediated by lysosomotropic agents [6, 14, 23] . In particular, recent reports have suggested that mast cells may be highly prone to 6 cells/ml) from three horses were cultured with the indicated concentrations of LLME. Non-treated cells were used as control. The cell viability was measured at the time points indicated using the Cell Titer Blue viability assay. Data represent means AE SEM (n = 3). The relative viability is normalized to control. * P < 0.05; ** P < 0.01.
Scandinavian Journal of Immunology, 2017, 85, 30-34 undergo apoptosis in response to this type of compounds [9, 11, 12, 24] . The results presented here thus concur with the latter findings and extend them by showing that lysosomotropic agents, in addition to affecting cultured human and mouse cells, also are effective cytotoxic agents for equine mast cells. In addition, this is the first study in which lysosomotropic agents have been shown to be effective in inducing cell death of fully mature, in vivoderived airway mast cells of any species.
Previous studies have indicated that mast cells are more sensitive to lysosomotropic agents than are other types of cells [12, 24] . The present report thus adds to this notion by showing that lysosomotropic agents show selectivity for mast cells over several other leucocyte populations of the equine airway. However, it is notable that lymphocytes were also sensitive, although to a lesser extent as compared to the mast cell population. We do not at present know whether this represents a general reduction of lymphocytes or a reduction of a particular lymphocyte population. For example, given that LLME acts on mast cells by permeabilizing their secretory granules, we may hypothesize that granule-containing lymphocyte populations (in particular CD8 + cells) may be sensitive to LLME. However, this remains to be clarified.
Considering that macrophages previously have been shown to be sensitive to cell death induced by lysosomotropic agents [14] , it may be unexpected that the equine airway macrophages were largely resistant to LLME treatment. However, a plausible explanation for this discrepancy could be that macrophages might require higher concentrations of LLME than the dose interval used here to undergo cell death. Indeed, previous studies have generally employed considerably higher concentrations of LLME than those employed in this study. For example, macrophages have been shown to undergo apoptosis at 100-250 lM of LLME and concentrations in the millimolar range were required to induce apoptosis in B-and T cell lines [14] .
Mast cells are densely packed with secretory granules containing pro-inflammatory mediators [1] . Previous studies of human and murine mast cells have shown that lysosomotropic agents mediate granule permeabilization and subsequent release of the granule contents to the cytosol, which in turn activates pro-apoptotic compounds leading to apoptosis [8, 12, 25] . In agreement with an apoptotic mechanism of cell death induced by LLME, we here detected apoptotic bodies in both lymphocytes and mast cells that had been treated with LLME.
In this study, we focused on LLME, a prototype lysosomotropic agent whose mechanism of action is well defined [6] [7] [8] . However, we have previously shown that other types of lysosomotropic compounds, siramesine [26] and mefloquine [10] , also promote mouse and human mast cell apoptosis. We may thus anticipate that such agents are effective also against equine airway mast cells. However, this remains to be demonstrated. Mast cells are widely recognized as effector cells in allergies and atopic asthma, and there is growing evidence supporting a detrimental role of mast cells in other disorders such as contact dermatitis, cancer and atherosclerosis [3, 4] . A number of drugs have been designed to inhibit mast cell functions, including receptor antagonists for mediators as well as mast cell stabilizers that prevent degranulation [27] . However, there is still a shortage of therapeutic regimens that cause a global blockade of detrimental mast cell activities. Based on this study, a potential therapeutic strategy to achieve this goal could thus be to administer lysosomotropic agents, thereby inducing mast cell apoptosis accompanied by a general blockade of mast cell function. For example, we may envision that lysosomotropic agents might be effective as treatment strategies in disorders such as mastocytosis and allergic conditions related to the airways.
